Gelonghui October 30th | Nanjing Pharmaceutical (600713.SH) announced the third quarter report of 2024, with the company's revenue in the first three quarters of 40.938 billion yuan, a year-on-year increase of 0.97%; net income attributable to shareholders of the listed company was 0.442 billion yuan, a year-on-year increase of 0.36%; basic earnings per share was 0.34 yuan.
南京医药(600713.SH)：前三季度净利润4.42亿元，同比增长0.36%
Nanjing Pharmaceutical (600713.SH): The net income for the first three quarters was 0.442 billion yuan, a year-on-year increase of 0.36%.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated